Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

NCT00498927 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG: temozolomide
GENETIC: protein expression analysis
GENETIC: reverse transcriptase-polymerase chain reaction
OTHER: diagnostic laboratory biomarker analysis
OTHER: immunoenzyme technique

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]